Oncology News

Multiple inflammation scores were not associated with an increased risk for hepatocellular carcinoma recurrence after liver transplantation, according to study data.

In a new study, patients with hepatocellular carcinoma who were treated with sorafenib plus radiofrequency ablation, or RFA, had increased overall survival and lower tumor recurrence rates vs. patients treated with RFA alone.

BOSTON — Cost of care for hepatocellular carcinoma, or HCC, was higher among patients with HCC and hepatitis C virus infection who underwent liver transplantation compared with patients who did not undergo transplant, according to data presented at The Liver Meeting.

In patients with hepatocellular carcinoma in the United States, Switzerland or Singapore, liver resection was more cost-effective than cadaveric liver transplantation, according to study data.

BOSTON — While men are at higher risk for developing hepatocellular carcinoma among patients with primary biliary cirrhosis, known as PBC, disease stage and biochemical response can be used to further stratify the risk in this population, according to data presented at The Liver Meeting.

BOSTON — Compared with single brush cytology, repeated brush cytology with or without fluorescence in situ hybridization increased sensitivity and specificity for detecting dysplasia or cholangiocarcinoma in primary sclerosing cholangitis patients prior to liver transplantation, according to data presented at The Liver Meeting.

Many pediatric patients with hepatoblastoma achieved radiographic resectability after two cycles of chemotherapy compared with four cycles, creating a potential opportunity to reduce the amount of chemotherapy and its complications, according to study researchers.

Initiation of the phase 3 OPTIMA study has been approved in Europe via its centralized Voluntary Harmonization Procedure, or VHP, to test the safety and efficacy of a potential primary liver cancer drug, according to a press release. 

Patients with hepatocellular carcinoma undergoing transarterial chemoembolization therapy and treated with a daily dose of brivanib did not have improved overall survival, according to clinical results.

Chemotherapy, transarterial chemoembolization and successful biliary drainage were effective in improving overall survival among patients with unresectable hepatocellular carcinoma with obstructive jaundice, researchers from Korea found.